A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 19 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2018 According to a BiondVax Pharmaceuticals media release, update on this trial will be presented at the Universal Influenza Vaccines 2018 Conference.